Tuesday 31 October 2017

India’s ceramic industry is looking to almost double its turnover to Rs 50,000 crore by 2020

Mr. Nilesh Jetpariya President(Wall Tiles Division-Morbi Ceramic Associations, Mr. K. G. Kundariya President (Vitrified Tiles Division) Morbi Ceramic Associations, Mr. Sandip Patel CEO VIBRANT CERAMICS EXPO & SUMMIT Photo By Sachin Murdeshwar / HPN
Mumbai, 31st October-2017 (HPN) :Vibrant Ceramics Expo & Summit 2017 held its press meets in Mumbai on 31st October, 2017. The primary reason to visit Mumbai was to increase the awareness among the Ceramic Industry and also to prove the fact that they stand second after China when it comes to Ceramic Industry. Also, another noteworthy observation was made during the meet that if Indian Ceramics Industry starts importing Ceramics from Morbi, Gujarat, India can overtake all other nations who top the list in this industry like China.
Vibrant Ceramics Expo and Summit (VCES), 2017 is being held from 16 to 19 November 2017 at Exhibition Center, near the town hall, Gandhinagar Gujarat . The event is spread across 50,000 square meter area with more than 250 exhibitors, 400+ brands, and ceramics in several sizes and designs under one roof.
Shri Nilesh Jetpariya – President, Vibrant Ceramics Expo & Summit-2017 said “India is the second largest tiles market in the world. While the global tiles production grew at an annualized rate of 6.3% for the period 2006-2013, tiles production in India grew almost double at 12.0% during the same period. Ceramic tiles that accounts for close to 60% of the total tiles demand in India is expected to grow at a CAGR of 8.7% for the period 2014-2019.”
He added “Ceramics industry, in line with the key agenda of the Government of India of Make in India, Skill India, and Swachh Bharat Abhiyaan amongst others. It is our constant Endeavour to keep innovating and contribute to the country’s economic growth and create further employment across states. At present, we are contributing to close to $ 4 billion in revenues and employ more than 10 lakhs skilled and unskilled personnel.”
Shri Sandip Patel – CEO, Vibrant Ceramics Expo & Summit-2017 said“Technology transfer, investment, joint ventures, B2B as well as B2G networking opportunities will be key highlights at the conference, while the exhibition will showcase the latest technology, ceramic tiles, sanitary-ware, and bath-fittings. Vibrant Ceramics is the initiative that aims towards unifying and synergizing the key players in the ceramics industry. We shall bring forward all sorts and types of business resources to a common destination to enable flawless interaction, channeling and networking.”
The first edition of Vibrant Ceramics held last year witnessed more than 610 foreign delegates from more than 22 countries which are going to be far surpassed this year with participation of over 2500 overseas buyers from 65+ countries. The event witnessed an overall footfall of over one lakh visitors over four days. By the end of the event, the sector saw business worth Rs. 500 crores and an order pipeline of about Rs. 1300 cr.s
​The road-shows for Vibrant Ceramic 2017 conducted in nearly 65 countries globally, which the organizers would be visiting personally along-with the 100 smart cities of India.
Delegates from Australia, Brazil, Cambodia, China, Canada, France, Germany, Indonesia, Italy, Jordan, Kenya, Latvia, Madagascar, Mauritius, Mayotte, Mexico, Nepal, Oman, Philippines, Poland, Qatar, Russia, Saudi Arabia, Senegal, South Africa, Spain, Sri Lanka, Tanzania, Uganda, United Arab Emirates, United Kingdom, United States, Serbia and much more.ENDS

Serum Institute of India in partnership with Massachusetts Medical School, USA unveils advanced Rotasiil vaccine, and Rabishield monoclonal antibody globally

Mumbai : Adar Poonawalla, CEO of Serum Institute of India with Michael Collins, MD Chancellor, University of Massachusetts Medical School (R) and Mark Klempner ,MD Executive, VC Mass Biologic, Professor of Medicicine, University of Massachusetts Medical School and Dr Rajeev Dhere during the event of Serum Institiute of India unveiling advanced Rotasiil vaccine and Rabishied monoclonal antibody globally ~developed in partnership with Massachusettd Medical School, USA in Mumbai on Tuesday. Photo By Sachin Murdeshwar / HPN
  • MUMBAI, 31 October, 2017 (HPN) : In a major breakthrough, Pune based Serum Institute of India, a part of Cyrus Poonawalla Group and the world’s largest manufacturer of vaccines, today announced the unveiling of its much-awaited Rotasiil vaccine and Rabishield, Rabies monoclonal antibody. Rabishield has been developed in research partnership with Massachusetts Medical School, USA.

The global launch was held today in Mumbai which was attended byMichael F Collins, MD Chancellor, University of Massachusetts Medical Schools and Marks S Klempner, MD Executive, Vice Chancellor- Mass Biologic, Professor of Medicine University of Massachusetts Medical School.
The availability of Rotasiil and Rabishield worldwide will help reduce deaths caused due to Rotavirus and Rabies which cause fatal diseases.
The newly developed Rabishield is the World’s first recombinant rabies monoclonal antibody. It will help prevent Rabies, a 100% fatal disease which does not have cure till date, but is almost 100 % preventable. Rabies is reported to cause two deaths every hour in India. It is transmitted to humans after an exposure via bites or scratches from both domestic and wild animals like dogs, cats, monkeys, wolves, coyotes, jackals, raccoons, mongooses, skunks and bats which are the reservoirs or vectors.
“Our new drug – Rabishield – is a first-of-its-kind product for passive immunization against Rabies. Since the new drug will be 25% cheaper than the existing rabies immunoglobulins, it would meet the needs of the poor countries,” said Mr. Adar Poonawalla, Chief Executive Officer, Serum Institute of India, at a press conference in Mumbai.
Rotasiil is the World’s first thermostable pentavalent Rotavirus vaccine containing the G9 strain to help prevent the spread of Rotavirus which causes Diarrhoea mostly in babies and is often accompanied by vomiting and fever, leading to severe dehydration. It is reported that around 100,000 rotavirus related deaths occur in India.
According to Mr. Poonawalla, “Scientists have been working on this Rotavirus vaccine for the last eight years. We had decided to develop a heat-stable vaccine to overcome the absence of cold-chain in many poor countries.”
About Serum Institute of India:Serum Institute of India, a part of Cyrus Poonawalla Group, is the world’s largest manufacturer of vaccines. It sells about 1.3 billion doses a year globally across 147 countries. About 65% children in the world have received at least one vaccine made by Serum Institute of India, whose products are available in over 147 countries.
Started in 1966 by Dr. Cyrus Poonawalla, Serum Institute of India has over the years metamorphosed into the world’s largest manufacturer of vaccines, thus saving millions of lives. Ends

HDFC Standard Life Insurance Company Limited – Initial Public Offer to open on Tuesday, November 7, 2017, and to close on Thursday, November 9, 2017 with the Price Band fixed from ₹275 per Equity Share to ₹290 per Equity Share

Mr. Amitabh Chaudhry, (Managing Director & CEO, HDFC Standard Life Insurance Company Limited), Mr. Deepak Parekh (Chairman, HDFC Standard Life Insurance Company Limited) and Mr. Keki Mistry (Director, HDFC Standard Life Insurance Company Limited) at the HDFC Standard Life Insurance IPO Press conference in Mumbai Photo By Sachin Murdeshwar / HPN
MUMBAI, (HPN): HDFC Standard Life Insurance Company Limited (the “Company” or “Issuer“) proposes to open on Tuesday, November 7, 2017, an initial public offering up to 299,827,818 Equity Shares of face value of  10 each (“Equity Shares”) which comprises of an offer for sale of 191,246,050 Equity Shares by Housing Development Finance Corporation and up to 108,581,768 Equity Shares by Standard Life (Mauritius Holdings) 2006 Limited (together “The Promoter Selling Shareholders” and such offering (“The Offer”). The Offer comprises of Net Offer to the Public of up to 266,895,517 Equity Shares (“Net Offer”), a reservation of up to 2,144,520 Equity Shares (constituting up to 0.11% of the Post Offer Paid Up Equity Share Capital) for purchase by the eligible HDFC Life Employees (“HDFC Life Employee Reservation Portion”), reservation of up to 805,000 Equity Shares (constituting up to 0.04% of the Post Offer Paid Up Equity Share Capital) for purchase by the eligible HDFC Employees (“HDFC Employee Reservation Portion”) and reservation of up to 29,982,781 Equity Shares (constituting up to 1.49% of Post-Offer paid up Equity Share Capital) for purchase by eligible HDFC Shareholders (“HDFC Shareholders Reservation Portion”). The Offer shall constitute 14.92% of the fully diluted Post-Offer Paid-up Equity Share Capital of the Company, ie; assuming all vested employee stock options and the Net Offer shall constitute 13.28% of the fully vested Post-Offer Paid-up Equity Share Capital of the Company i.e. assuming exercise of all vested employee stock options.
The Price Band for the Offer is fixed from  275 per Equity Share to  290 per Equity Share. Bids can be made for a minimum of 50 Equity Shares and in multiples of 50 Equity Shares thereafter. The Offer will close on Thursday, November 9, 2017.
The Company and the Promoter Selling Shareholders may, in consultation with the Managers to the Offer, consider participation by Anchor Investors. Such Anchor Investors shall Bid during the Anchor Investor Bidding Date; i.e., one Working Day prior to the Offer Opening Date, on which Bids by Anchor Investors shall be submitted and allocation to Anchor Investors shall be completed i.e. November 6, 2017.
The Global Co-ordinators and Book Running Lead Managers are Morgan Stanley India Company Private Limited, HDFC Bank Limited, Credit Suisse Securities (India) Private Limited, CLSA India Private Limited and Nomura Financial Advisory and Securities (India) Private Limited. The Book Running Lead Managers are Edelweiss Financial Services Limited, Haitong Securities India Private Limited, IDFC Bank Limited, IIFL Holdings Limited and UBS Securities India Private Limited.
The Equity Shares offered in the Offer are proposed to be listed on the BSE and the NSE.
The Offer is being made in accordance with Regulation 26(1) of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009, as amended (“ICDR Regulations”), wherein not more than 50% of the Net Offer shall be allocated on a proportionate basis to Qualified Institutional Buyers (“QIBs”), provided that the Company and the Promoter Selling Shareholders, in consultation with the Managers, may allocate up to 60% of the QIB Portion to Anchor Investors on a discretionary basis, of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the Anchor Investor Allocation Price, in accordance with the SEBI Regulations. 5% of the QIB Portion (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only, and the remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIB Bidders (other than Anchor Investors), including Mutual Funds, subject to valid Bids being received at or above the Offer Price. Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35% of the Net Offer shall be available for allocation to Retail Individual Investors in accordance with the ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All Bidders, other than Anchor Investors, are required to mandatorily utilise the Application Supported by Blocked Amount (“ASBA”) process providing details of their respective bank accounts which will be blocked by the SCSBs, to participate in this Offer.
Capitalised terms not otherwise defined in this press release shall have the meanings given to them in the RHP.ENDS

Friday 27 October 2017

EXPO INDONESIA 2017~“Featuring Indonesian Trade, Tourism and Investment Potentials”

Mumbai, 27 October, 2017 (HPN) :The Consulate General of the Republic of Indonesia in Mumbai continues to conduct various activities to developing bilateral relations and cooperation between Indonesia and India under the jurisdiction of its mission. Hence, theConsulate General of the Republic of Indonesia,Mumbai with the aim to promote the Trade, Tourism and Investment opportunities will organize a Solo Exhibition entitled “EXPO INDONESIA 2017″, to be held at World Trade Centre (WTC), Mumbai, on November 3-5, 2017. 47 Indonesian companies will participate at EXPO INDONESIA 2017, as exhibitors, featuring various products such as: furniture, health-care products, food, home-care products, batik, and handicraft products such as handbags, accessories etc.
The series of events will be held during Expo Indonesia 2017, such as Seminar on Trade and Investment, “Enhancing Trade and Investment Relations between Indonesia and India”, Seminar on Tourism, “Experience Travel and Tourism in Wonderful Indonesia : An Endless Destination”, B2B Meetings for trade and Investments, Table Top meetings for Travel and Tourism Industry, and Indonesian food vendors.
Expo Indonesia 2017 is the second exhibition being organized by this mission after the last event organized in year 2016. The Expo Indonesia 2017 is the continued efforts of the recent success leading a business delegation of 150 business delegates from India attending the “Trade Expo Indonesia 2017”, October 11-15, 2017 in Jakarta, Indonesia, organized by the Ministry of Trade of the Republic of Indonesia. The event resulted into a significant transaction of US $ 105.114.000 resulting into a 25.13% increase compared to the year 2016.
Indonesia and India enjoy a high level mutual beneficial relation. The average value of bilateral trade between Indonesia and India in last five years have been reaching to around US $16 billion.
INDONESIA EXPO 2017 is also expected to further boost Indian tourists to Indonesia. Launching of Garuda Indonesia Airlines and AirAsia Indonesia airlines is also expected to further boost Indian tourists to Indonesia beyond Bali. An important note that for year of 2016, the increase number of Indian tourists to Indonesia was 28.42% with figures reaching to 3,76,802 compared to 293,415 in 2015. While Indian traveler now rank 5th among all sources of foreign tourist visitors to Bali. In 2016 a total of 186,638 Indian nationals came to Bali, an increase of 57.61% when compared to 2015.
India is one of the most important engines of the world’s economic growth. The “Make in India” move is considered as a breakthrough to open the country’s economy for investment.
Indonesian companies are expected to invest in India to strengthen ties between both countries.The business partnership in sectors such as financing, automotive and textile must be increased and strengthened as both countries have such huge markets in those sectors.ENDS

Wednesday 25 October 2017

First Trio of Trade Fairs comprising pacprocess India, indiapack and food pex India is Ready to Kick Off


~ISPI Conference and drink technology India in Parallel
Mumbai, 25 th October, 2017 (HPN) :From 26 to 28 October 2017 the first edition of the trade fair trio comprising pacprocess India, indiapack and food pex India will rank top of the agenda at the Pragati Maidan Exhibition Centre in New Delhi. Forming part of the interpack alliance, this trio is the result of a cooperation between Messe Düsseldorf and the Indian Institute of Packaging (IIP). The ‘ISPI International Summit for Packaging Industry’ conceived and organised by the IIP and drink technology India by Messe München will be held concurrently with the fairs.
More than 200 companies have registered for these trade fairs and will be presenting solutions from fields such as packaging machines and machines and equipment for the manufacturing of pharmaceuticals and cosmetics, automation technology and components/auxiliaries as well as recycling and environmental technology (pacprocess India) on approximately 11,000 square metres. Also on display will be packaging materials and accessories as well as machinery and technology for the manufacturing of packaging and packaging aids (indiapack). The ranges of the trade fair trio of the interpack alliance are complemented with machines and equipment for the manufacturing of food, confectionary and bakery products (food pex India). drink technology India organised concurrently by Messe München focuses on the segments of beverages and liquid foods. Germany, China and Taiwan will organise official country pavilions.
The long established ‘ISPI  International Summit for Packaging Industry’ now organised by the Indian Institute of Packaging (IIP) in parallel with these trade fairs this year comes under the heading of Packaging  the Growth Driver. This title was chosen in view of the importance of the packaging industry for economic growth in India. The development of the process chain from
packaging raw materials to retail packaging is both an indicator of, and driver for, this dynamically growing economy. Focal themes of the summit, centring on the promising Indian market, include technical issues associated with packaging food, pharmaceuticals, cosmetics and healthcare products. Further subjects include sustainable packaging and zero-waste approaches to packaging as well as packaging design and printing.
The trade fair trio comprising pacprocess India, indiapack and food pex India is held every year. Next year Mumbai will host the event. Pursuant to the cooperation agreement recently concluded with the interpack alliance the Italian machinery producers association UCIMA will support marketing of the Indian events by canvassing visitors and organising an Italian pavilion from 2018. The drink technology India trade fair organised by Messe München will also be held concurrently again next year.ENDS

The New India Assurance Company Limited’s initial public to open on Wednesday, November 01, 2017 and closes on Friday, November 03, 2017, with Price Band of Rs. 770 to Rs. 800 per equity share each of Face Value of Rs. 5/- each

Mumbai : G Srinivasan, CMD of The New India Assurance Company Limited with Hemant Rokade, Director & GM (L) and Anil Kumar, Director & GM (R) during announcement the company IPO in Mumbai on Wednesday. Photo/25.10.2017 By Sachin Murdeshwar HPN
MUMBAI, October 25, 2017 (HPN) : The New India Assurance Company Limited (“Company”), will be launching its initial public offering which is scheduled to open on Wednesday, November 01, 2017 and close on Friday, November 03, 2017, with a price band of Rs. 770 to Rs. 800 per Equity Share of face value of Rs. 5/- each of the Company (the “Equity Shares”). A discount of Rs. 30 on the Offer Price is being offered to Retail Individual Investors (“Retail Discount”) and to Eligible Employees Bidding in the Employee Reservation Portion (“Employee Discount”).
The initial public offering of up to 120,000,000 Equity Shares of the Company consisting of a fresh issue of up to 24,000,000 equity shares (“Fresh Issue”) and an offer for sale of up to 96,000,000 equity shares (“Offer For Sale” and together with the fresh issue, the “Offer”) by The President of India, acting through the Ministry of Finance, Government of India (the “Selling Shareholder”). The Offer and the Net Offer shall constitute 14.56% and 14.13%, respectively of the post-Offer paid-up Equity Share capital of the Company.
The Offer also includes a reservation of up to 3,600,000 Equity Shares for subscription by Eligible Employees (the “Employee Reservation Portion”). The Offer will comprise the Net Offer of up to 116,400,000 Equity Shares and the Employee Reservation Portion of up to 3,600,000 equity shares.
The Company proposes to utilize the net proceeds of the Fresh Issue towards meeting future capital requirements which are expected to arise from the growth and expansion of business, improving solvency margin and consequently solvency ratio of the company.
In terms of Rule 19(2)(b)(iii) of the Securities Contracts (Regulation) Rules, 1957, as amended (the “SCRR”), the Offer is being made for at least 10% of the post-Offer paid-up equity share capital of the Company. The Offer is through the Book Building Process, in reliance of Regulation 26(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer shall be available on a proportionate basis to Qualified Institutional Buyers (“QIBs Portion”). Such numbers of Offered Shares representing 5% of the QIB Portion shall be available for allocation on a proportionate basis to Mutual Funds only, subject to valid bids being received from them at or above the Offer Price. The remainder of the QIB Portion shall be available for allocation on a proportionate basis to all QIBs, including Mutual Funds, subject to valid Bids being received from them at or above the Offer Price.
Further, not less than 15% of the Net Offer shall be available for allocation on a proportionate basis to Non-Institutional Bidders and not less than 35% of the Net Offer shall be available for allocation, in accordance with the SEBI ICDR Regulations, to Retail Individual Investors, subject to valid Bids being received from them at or above the Offer Price. Further, up to 3,600,000 Equity Shares shall be offered for allocation and Allotment on a proportionate basis to the Eligible Employees Bidding in the Employee Reservation Portion, conditional upon valid Bids being received from them at or above the Offer Price.
All Bidders are required to mandatorily utilise the Applications Supported by Blocked Amount (“ASBA”) process by providing the details of their respective bank accounts in which the corresponding Bid Amount will be blocked by the Self Certified Syndicate Banks (“SCSBs”).
Kotak Mahindra Capital Company Limited, Axis Capital Limited, IDFC Bank Limited, Nomura Financial Advisory and Securities (India) Private Limited and YES Securities (India) Limited are the Book Running Lead Managers (“BRLMs”) to the Offer. The Registrar to the Offer is Link Intime India Private Limited.
The Equity Shares of The New India Assurance Company Limited are proposed to be listed on the National Stock Exchange of India and BSE Limited.
Capitalised terms not otherwise defined in this press release shall have the meanings given to them in the RHP.ENDS

Tuesday 24 October 2017

Mahindra Logistics Limited – IPO to open on Tuesday, October 31, 2017, and to close on Thursday, November 2, 2017

(L-R) – Mr. S Ramesh, Kotak Mahindra Capital Company Limited, Mr. Nikhil Nayak, Chief Financial Officer, Mahindra Logistics Limited, Mr. Zhooben Bhiwandiwala, Chairman, Mahindra Logistics Limited, Mr. Pirojshaw Sarkari, CEO, Mahindra Logistics Limited and Mr. Parag Shah, Director, Mahindra Logistics Limited and Mr. Chirag Negandhi, Axis Capital Limited at a press conference held today in Mumbai to announce the forthcoming IPO of Mahindra Logistics Limited. The issue opens for subscription on Tuesday 31st October 2017 and closes on Thursday 2nd November 2017. Price band of the issue is Rs 425 per equity share to Rs 429 per equity share.- Photo By Sachin Murdeshwar / HPN
Mumbai, October 24, 2017 (HPN) : Mahindra Logistics Limited (the “Company“) proposes to open on Tuesday, October 31, 2017, an initial public offering of up to 19,332,346  Equity Shares of face value of Rs. 10 each (the “Equity Shares”) of the Company for cash within a Price Band of Rs. 425 per Equity Share to Rs. 429 per Equity Share through an Offer for Sale of (I) up to 9,666,173 Equity Shares by Mahindra & Mahindra Limited (the Promoter); (II) up to 9,271,180 Equity Shares by Normandy Holdings Limited; and (III) up to 394,993 Equity Shares by Kedaara Capital Alternative Investment Fund – Kedaara Capital AIF 1, (the “Offer for Sale” or the “Offer” and such Shareholders offering their respective Equity Shares in the Offer for Sale are collectively hereinafter referred to as the “Selling Shareholders” and individually as a “Selling Shareholder”). The Offer includes a reservation of up to 125,000 Equity Shares for subscription by Eligible Employees (as defined in the RHP) (the “Employee Reservation Portion”). The Offer less the Employee Reservation Portion is hereinafter referred to as the “Net Offer” and such Net Offer aggregates up to 19,207,346 Equity Shares. The Offer and the Net Offer shall constitute 27.17% and 27.00%, respectively, of the post-Offer paid-up Equity Share capital of the Company. The Offer includes a discount of Rs. 42 per equity share on the Offer Price to Eligible Employees (the “Employee Discount”).
The BRLMs to the Offer are Kotak Mahindra Capital Company Limited and Axis Capital Limited.
The Equity Shares proposed to be issued through the RHP are proposed to be listed on BSE and NSE.
The Offer is being made through the Book Building Process and in compliance with Regulation 26(1) of the SEBI ICDR Regulations, wherein not more than 50% of the Net Offer shall be available for allocation on a proportionate basis to Qualified Institutional Buyers (“QIBs”) (the “QIB Category”), provided that the Company and the Selling Shareholders, in consultation with the BRLMs, may allocate up to 60% of the QIB Category to Anchor Investors, on a discretionary basis (the “Anchor Investor Portion”), of which one-third shall be reserved for domestic Mutual Funds, subject to valid Bids being received from domestic Mutual Funds at or above the price at which allocation is made to Anchor Investors. Further, 5% of the QIB Category (excluding the Anchor Investor Portion) shall be available for allocation on a proportionate basis to Mutual Funds only. The remainder of the QIB Category shall be available for allocation on a proportionate basis to QIBs, subject to valid Bids being received from them at or above the Offer Price. Further, not less than 15% of the Net Offer will be available for allocation on a proportionate basis to Non-Institutional Investors and not less than 35% of the Net Offer will be available for allocation to Retail Individual Investors, in accordance with the SEBI ICDR Regulations, subject to valid Bids being received at or above the Offer Price. All Bidders (except Anchor Investors) shall mandatorily participate in this Offer only through the Application Supported by Blocked Amount (“ASBA”) process, and shall provide details of their respective bank account in which the Bid amount will be blocked by the SCSBs. Anchor Investors are not permitted to participate in the Anchor Investor Portion through the ASBA process. For details, see “Offer Procedure” on page 318 of the RHP.ENDS
The RHP is available on the website of the SEBI at www.sebi.gov.in as well as on the websites of the book running lead managers, Kotak Mahindra Capital Company Limited and Axis Capital Limited, respectively.

Kokuyo Camlin Launches Colouring Kit for Adults

Mumbai, October 24th 2017 (HPN)  :  Kokuyo Camlin, known for its innovative stationery and colouring products has recently launched the Adult Colouring Kit. Colouring as an activity is generally associated with kids and not adults but given the global trend of adult colouring books becoming immensely popular across the world, it turns out that adults too have been pursuing coloring as a hobby  especially since it is known to have a calming effect on the mind and a great stress buster.
According to psychologists, Colouring activity can have a de-stressing effect with adults because when we focus on a certain activity, we are thoroughly involved with that activity and not our worries simultaneously it also reinvigorates our imagination and takes us back to our childhood days when we were happy and less stressed.
Saumitra Prasad, Chief Marketing Officer, Kokuyo Camlin Ltd said, “In countries like Europe and North America, coloring books for adults have become immensely popular. We have launched the Adult Coloring kits — keeping in mind that it will encourage adults to pursue colouring as a hobby. Also art therapists and researchers have been touting the therapeutic benefits of coloring for quite some time. We hope that the Adult Coloring Kits will become immensely popular with adults in India too.”
The Kokuyo Camlin Adult Colouring Kit comes along with 24 shades of Camlin Bi-Colour Pencils, Sharpener and a Colouring Book which has 32 hand-drawn illustrations of mandalas, animals, flowers and forests. It is available at all retails stores at a price of Rs 399/-ENDS.

Monday 16 October 2017

SRCC Children’s Hospital hosts mega awareness campaign on Rett Syndrome

Photo By HPN
In Center from Left Dr Anaita Hegde, Consultant Pediatric Neurology, NHSRCC Children’s Hospital, Smt. Anita Garware and Commissioner of Police Mumbai, Shri Dattatray Padsalgikar at the Rett Syndrome Awareness Seminar arranged at the Narayana Health SRCC Children’s Hospital today. Prominent doctors from Pan India and over 30 children suffering from Rett syndrome with over 150 parents attended the seminar. The 10th National Rett Syndrome Awarness Symposium was organized by Narayana Health SRCC Children’s Hospital in association with Indian Rett Syndrome Foundation.
Mumbai, October 15, 2017 (HPN) : SRCC Children’s Hospital along with Indian Rett Syndrome Awareness Foundation and Parents Support Group of Delhi, for the first time in Mumbai, conducted a mega awareness seminar among parents on Rett Syndrome (primarily a neuro development disorder found prominently among girl children). Over 30 children suffering from Rett Syndrome and over 150 parents pan India attended the interactive panel discussion with Doctors and Experts, many of them coming from Delhi.
Commissioner of Police, Mumbai, Shri Dattatray Padsalgikar was the Chief Guest for this event. Specialists doctors (Brig.) Dr K. S. Rana (Delhi), Dr Anaita Hegde, Dr Shiraz Vazifdar, Dr Mala Jagtiani, Mrs Roshan Kore, spoke on various topics related to Rett Syndrome.
Dr Sonu Udani, Director Pediatric Care, SRCC Children’s Hospital, managed by Narayana Health, said, “Parents knowledge and support to these children are essential, they need to understand that such children (mostly girls) suffer from physical growth, hearing and vision problems, balancing problem, seizure’s etc and take necessary steps to manage them. Over a year, the child shows autism symptoms and this disorder generally develops after the child is 2 years of age and in few cases, symptoms are observed even after the child is 1 year old. Around 1 in 10000 girls suffer from this syndrome.”
SRCC Children’s Hospital managed by Narayana Health at Haji Ali Park, offers an exclusive super-specialty consultation with a holistic approach and in a child friendly manner. SRCC Children’s Hospital brings together this expertise under one umbrella to provide much needed care in a state-of-the-art facility.
The hospital is a state of the art multispecialty tertiary care hospital dedicated to treating infants, children and young adults. This facility provides cutting-edge super specialists medical care in over 20 specialities.
Some of the key takeaways from the Seminar:
·         Rett syndrome (RS), one of the commonest causes of profound cognitive impairment in girls and women, was first recognized in the 1960s and the first report from India was in 1994. Though RS has a prevalence of 1 per 10000 to 1 per 22000 in India it is confined to very few case reports. This may be related to under diagnoses of the condition or misdiagnosis of these children as cerebral palsy or autism.
·         There is not medical cure available today on this disorder and medical trials are in process at various medical institutions and research centres in India, USA and Europe
·         Over 30 Rett Syndrome disorder children and 150 parents from Pan India attended the awareness seminar
·         Parents Support Group (Delhi) was representing the parents of the children suffering from Rett Syndrome
·         Parents express the challenges to deal with such children and the efforts they have been taking to give best possible medical aid to their children
·         Mostly girls are found with Rett Syndrome disorder and every 1 girl on 10,000 across the world is found with this disorder
·         Some Common signs and symptoms of Rett syndrome:
o   Slowed growth. Brain growth slows after birth. Smaller than normal head size is usually the first sign that a child has Rett syndrome. It generally starts to become apparent after 6 months of age. As children get older, delayed growth in other parts of the body becomes evident.
o    Loss of normal movement and coordination. The most significant loss of movement skills (motor skills) usually starts between 12 and 18 months of age. The first signs often include a decrease of hand control and a decreasing ability to crawl or walk normally. At first, this loss of abilities occurs rapidly and then continues more gradually.
o   Loss of communication and thinking abilities. Children with Rett syndrome typically begin to lose the ability to speak and to communicate in other ways. They may become uninterested in other people, toys and their surroundings. Some children have rapid changes, such as a sudden loss of speech. Over time, most children gradually regain eye contact and develop nonverbal communication skills.
o    Abnormal hand movements. As the disease progresses, children with Rett syndrome typically develop their own particular hand patterns, which may include hand wringing, squeezing, clapping, tapping or rubbing.
o    Unusual eye movements. Children with Rett syndrome tend to have unusual eye movements, such as intense staring, blinking or closing one eye at a time.
o   Breathing problems. These include breath-holding (apnea), abnormally rapid breathing (hyperventilation), and forceful exhalation of air or saliva. These problems tend to occur during waking hours, but not during sleep.
o   Irritability. Children with Rett syndrome become increasingly agitated and irritable as they get older. Periods of crying or screaming may begin suddenly and last for hours.
o   Abnormal behaviors. These may include sudden, odd facial expressions and long bouts of laughter, screaming that occurs for no apparent reason, hand licking, and grasping of hair or clothing.
o   Seizures. Most people who have Rett syndrome experience seizures at some time during their lives. Symptoms vary from person to person, and they can range from periodic muscle spasms to full-blown epilepsy.
o   Abnormal curvature of the spine (scoliosis). Scoliosis is common with Rett syndrome. It typically begins between 8 and 11 years of age.
o   Irregular heartbeat (dysrhythmia). This is a life-threatening problem for many children and adults with Rett syndrome.
o   Constipation. This is a common problem in people with Rett syndrome.
·         This syndrome is observed due to any faulty DNA combination at the time of a child’s development before its birth
·         Frequent urination, breathlessness, breathing related attacks, fits, anxiety and mood swings, sweating or body becoming cold are some of the common autonomic disturbances observed in such children.
·         There could be development delays observed in such children like balancing, walk, speech, sight etc
·         It has been observed through experience of doctors and specialists that Music Therapy, Physio Therapy or Parents involvement in any games/ play can help such children to curb their anxiety and calms their mood
·         Parents positive attitude and patience towards treatment of these children
·         Injectable or oral medicines can be given to menstrual issues of the girl child. Over the period with proper consultation of Gynaecologist and with a thorough understanding and consent of parents, a hysterectomy surgery can be done. 
SRCC Children’s Hospital, managed by Narayana Health, is a multi-speciality hospital exclusively for children. Of the 207 beds currently operational, 87 have been allocated for Multispecialty Critical Care covering new-borns to adolescents.
It has taken critical care to a higher level with the concept of Level IV care where a qualified team of Paediatric Intensivists will be able to provide Emergency Life Support (ELS) for children with failure of their vital organs including heart, lungs and kidneys. Also available are a team of specialists in Cardiac sciences, Neurosciences, Hematology- Oncology, infectious diseases, Endocrinology, Orthopaedics, ENT, Gastroenterology, diagnostics services and nephrology amongst others.ENDS

गोदरेज एंड बॉयस ने डाई पैरामीटर मॉनिटरिंग के लिए पेश की स्मार्ट कनेक्टेड डाई कास्टिंग डाई

~ स्मार्ट कनेक्टेड डाई कास्टिंग डाई फाउंड्री की कार्यकुशलता को बेहतर बनाती है, जिससे डाई की आयु 10% बढ़ जाती है और प्रति पीस लागत 10% कम हो ...